ArticleUnited European gastroenterology journal2026
Clinical and Mechanistic Association Between Intestinal Permeability and the Gut Microbiome in Cirrhosis: Role of Phascolarctobacterium.
Article in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections
Microbiome and Sarcopenia in Patients With Liver Cirrhosis: A Prospective Controlled Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIn patients with liver cirrhosis, intestinal permeability and the composition of the gut microbiome are altered. Thus, the microbiome might be a therapeutic target for the treatment of both liver diseases and intestinal permeability. We aimed to investigate the relationship between the intestinal barrier and microbiome composition in cirrhosis and elucidate potential mechanisms for how bacteria influence permeability.
methodsWe analyzed the fecal permeability biomarker zonulin by ELISA and microbiome composition by 16s rDNA sequencing in a discovery (n = 78) and a validation cohort (n = 90) of patients with liver cirrhosis. In the validation cohort, we analyzed the composition of the fecal metabolome by NMR spectroscopy. For mechanistic exploration, an intestinal barrier cell culture model using T84 cells was used.
resultsIn the discovery cohort (n = 78, 77% Child-Pugh Grade A, 21% Child-Pugh Grade B, 3% Child-Pugh Grade C), decreasing zonulin levels in stool over 6 months were associated with higher Phascolarctobacterium abundance in the microbiome. Phascolarctobacterium was associated with better liver function (lower bilirubin, p = 0.04, INR p = 0.04, MELD Score, p = 0.02). Lower Phascolarctobacterium levels were observed in decompensated cirrhosis and were associated with 36-month mortality in two cohorts. Metabolomics analysis showed an association between Phascolarctobacterium and lower succinate levels. Succinate increased gut permeability in vitro, and Phascolarctobacterium succinatutens strains improved the intestinal permeability, potentially by alleviating the effect of succinate.
conclusionPhascolarctobacterium may represent a candidate biomarker of adverse outcomes in cirrhosis and a promising target for further investigation as a next-generation probiotic involved in gut barrier function and succinate homeostasis.
trial registrationNCT01607528, NCT03080129.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.